| 臺大學術典藏 |
2021-01-06T08:23:27Z |
Treatment response to etanercept in methotrexate refractory juvenile idiopathic arthritis: an analysis of predictors and long-term outcomes
|
Su Y.;Yao-Hsu Yang;Chiang B.-L.; Su Y.; YAO-HSU YANG; Chiang B.-L. |
| 臺大學術典藏 |
2018-09-10T18:06:52Z |
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study
|
Tsai, M.-S. and Chang, S.-Y. and Lin, S.-W. and Kuo, C.-H. and Sun, H.-Y. and Wu, B.-R. and Tang, S.-Y. and Liu, W.-C. and Su, Y.-C. and Hung, C.-C. and Chang, S.-C.; CHING-HUA KUO; SHAN-CHWEN CHANG; HSIN-YUN SUN |
| 臺大學術典藏 |
2020-03-09T06:08:10Z |
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study
|
Tsai M.-S.;Chang S.-Y.;Shu-Wen Lin;Kuo C.-H.;Sun H.-Y.;Wu B.-R.;Tang S.-Y.;Liu W.-C.;Su Y.-C.;Hung C.-C.;Chang S.-C.; Tsai M.-S.; Chang S.-Y.; SHU-WEN LIN; Kuo C.-H.; Sun H.-Y.; Wu B.-R.; Tang S.-Y.; Liu W.-C.; Su Y.-C.; Hung C.-C.; Chang S.-C. |
| 臺大學術典藏 |
2020-06-18T08:25:54Z |
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study
|
Tsai M.-S.;Sui-Yuan Chang;Lin S.-W.;Kuo C.-H.;Sun H.-Y.;Wu B.-R.;Tang S.-Y.;Liu W.-C.;Su Y.-C.;Hung C.-C.;Chang S.-C.; Tsai M.-S.; SUI-YUAN CHANG; Lin S.-W.; Kuo C.-H.; Sun H.-Y.; Wu B.-R.; Tang S.-Y.; Liu W.-C.; Su Y.-C.; Hung C.-C.; Chang S.-C. |
| 臺大學術典藏 |
2020-09-30T03:22:26Z |
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study
|
Wu B.-R.; Tang S.-Y.; Liu W.-C.; Su Y.-C.; CHIEN-CHING HUNG; Chang S.-C.; Tsai M.-S.; Chang S.-Y.; Lin S.-W.; Kuo C.-H.; Sun H.-Y. |
| 臺大學術典藏 |
2017 |
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study
|
Wu B.-R.; Tang S.-Y.; HSIN-YUN SUN; Kuo C.-H.; Lin S.-W.; Chang S.-Y.; Tsai M.-S.; Chang S.-C.; Hung C.-C.; Liu W.-C.; Su Y.-C. |
| 臺大學術典藏 |
2020-12-30T02:44:13Z |
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study
|
Tsai M.-S.;Chang S.-Y.;Lin S.-W.;Kuo C.-H.;Sun H.-Y.;Wu B.-R.;Tang S.-Y.;Liu W.-C.;Su Y.-C.;Hung C.-C.;Shan-Chwen Chang; Tsai M.-S.; Chang S.-Y.; Lin S.-W.; Kuo C.-H.; Sun H.-Y.; Wu B.-R.; Tang S.-Y.; Liu W.-C.; Su Y.-C.; Hung C.-C.; SHAN-CHWEN CHANG |
| 臺大學術典藏 |
2021-06-04T06:23:11Z |
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study
|
Tsai M.-S.; Chang S.-Y.; Lin S.-W.; CHING-HUA KUO; Sun H.-Y.; Wu B.-R.; Tang S.-Y.; Liu W.-C.; Su Y.-C.; Hung C.-C.; Chang S.-C. |
| 臺大學術典藏 |
2022-09-07T06:39:18Z |
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic study
|
Tsai M.-S.; Chang S.-Y.; SHU-WEN LIN; Kuo C.-H.; Sun H.-Y.; Wu B.-R.; Tang S.-Y.; Liu W.-C.; Su Y.-C.; Hung C.-C.; Chang S.-C. |
| 高雄醫學大學 |
2008 |
Treatment results for children with acute myeloid leukemia inTaiwan
|
梁德成;張泰琮;TPOG團隊 |
| 國立臺灣大學 |
1999 |
Treatment Results of Carcinoma of the Nasal Cavity
|
許智捷; 鍾娜娜; 雷德; 丁禮莉; HSU, CHIH-CHIECH; CHUNG, NA-NA; LUI, LOUIS TAK; TING, LAI-LEI |
| 中國醫藥大學 |
2007-07 |
Treatment Results of Hypopharyngeal Cancer Based on Definitive Radiotherapy
|
陳邦瑜(Pang-Yu Chen); 楊世能(Shih-Neng Yang); 梁基安(Ji-An Liang); 蔡銘修(Ming-Hsui Tsai); 陳尚文(Shang-Wen Chen)*; 林芳仁 |
| 中國醫藥大學 |
2007-07 |
Treatment Results of Hypopharyngeal Cancer Based on Definitive Radiotherapy
|
陳邦瑜(Pang-Yu Chen); 楊世能(Shih-Neng Yang); 梁基安(Ji-An Liang); 蔡銘修(Ming-Hsui Tsai); 陳尚文(Shang-Wen Chen)*; 林芳仁 |
| 國立臺灣大學 |
2000 |
Treatment Results of the Tpog-Nhl92 Protocols for Childhood Non-Hodgkin's Lymphomas in Taiwan: A Report from the Taiwan Pediatric Oncology Group ( Tpog)
|
盧孟佑; LU, MENG-YAO |
| 臺大學術典藏 |
2018-09-10T03:32:24Z |
Treatment results of the TPOG-NHL92 protocols for childhood non-Hodgkin's lymphomas in Taiwan: A report from the Taiwan Pediatric Oncology Group (TPOG)
|
Yang, C.-P.;Hung, I.-J.;Jaing, T.-H.;Lin, K.-H.;Lin, D.-T.;Lu, M.-Y.;Liang, D.-C.;Chen, S.-H.;Liu, H.-C.;Hsiao, C.-C.;Shu, S.-G.;Chen, J.-S.;Chang, T.-T.;Chiou, S.-S.;Hsieh, Y.-L.;Lin, M.-T.;Lee, M.-T.;Peng, C.-T.;Cheng, S.-N.;Chen, R.-L.;Chen, B.-W.;Lin, K.-S.; KAI-HSIN LIN |
| 臺大學術典藏 |
2020-12-16T07:22:10Z |
Treatment results of the TPOG-NHL92 protocols for childhood non-Hodgkin's lymphomas in Taiwan: A report from the Taiwan Pediatric Oncology Group (TPOG)
|
Chen J.-S.; Chang T.-T.; Chiou S.-S.; Hsieh Y.-L.; Lin M.-T.; Lee M.-T.; Peng C.-T.; Cheng S.-N.; Chen R.-L.; Chen B.-W.; Lin K.-S.; Yang C.-P.;Hung I.-J.;Jaing T.-H.;Lin K.-H.;Lin D.-T.;Meng-Yao Lu;Liang D.-C.;Chen S.-H.;Liu H.-C.;Hsiao C.-C.;Shu S.-G.;Chen J.-S.;Chang T.-T.;Chiou S.-S.;Hsieh Y.-L.;Lin M.-T.;Lee M.-T.;Peng C.-T.;Cheng S.-N.;Chen R.-L.;Chen B.-W.;Lin K.-S.; Yang C.-P.; Hung I.-J.; Jaing T.-H.; Lin K.-H.; Lin D.-T.; MENG-YAO LU; Liang D.-C.; Chen S.-H.; Liu H.-C.; Hsiao C.-C.; Shu S.-G. |
| 國立成功大學 |
2023 |
Treatment Retention Rates of 3-monthly Paliperidone Palmitate and Risk Factors Associated with Discontinuation: A Population-based Cohort Study
|
Lin, C.-H.;Lin, H.-L.;Chiang, Chiang C.-L.;Chen, Y.-W.;Liu, Y.-F.;Yang, Yang Y.-K.;Tang, C.-H. |
| 臺大學術典藏 |
2021-09-13T05:41:53Z |
Treatment seeking and barriers to treatment for alcohol use in persons with alcohol use disorders and comorbid mood or anxiety disorders
|
Kaufmann C.N.; LIAN-YU CHEN; Crum R.M.; Mojtabai R. |
| 臺大學術典藏 |
2018-09-10T05:12:48Z |
Treatment strategies for developing class III patients
|
Chang, F.H.F.;Chang, J.Z.C.; JENNY ZWEI-CHIENG CHANG |
| 臺大學術典藏 |
2021-07-07T01:20:32Z |
Treatment strategies for developing class III patients
|
Chang F.H.F.; JENNY ZWEI-CHIENG CHANG |
| 臺大學術典藏 |
2018-06-28T23:19:06Z |
Treatment Strategy for Cr(VI)-Bearing Wastes
|
Lo, Kevin S. L.; Lin, Cheng-Fang; Lo, Kevin S. L.; 林正芳; Rou, Wei; Rou, Wei; Lo, Kevin S. L.; Lin, Cheng-Fang |
| 國立臺灣大學 |
1991-05 |
Treatment Strategy for Cr(VI)-Bearing Wastes
|
林正芳; Rou, Wei; Lo, Kevin S. L.; Lin, Cheng-Fang; Rou, Wei; Lo, Kevin S. L. |
| 國立臺灣大學 |
1992 |
Treatment Strategy for Cr(VI)-Bearing Wastes
|
Lin, C. F.; Rou, W.; 駱尚廉; Lin, C. F.; Rou, W.; Lo, Shang-Lien |
| 臺北醫學大學 |
2002 |
Treatment Strategy for Refractory Schizophrenia---Pharmacokinetic and Pharmacodynamic Interactions Between Clozapine and Fluvoxamine
|
盧孟良 |
| 臺北醫學大學 |
2002 |
Treatment Strategy for Refractory Schizophrenia---Pharmacokinetic and Pharmacodynamic Interactions Between Clozapine and Fluvoxamine
|
盧孟良 |
